Abstract Single nucleotide polymorphisms (SNPs) in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been associated with Alzheimer's disease (AD) in large meta-analyses. We aimed to determine whether established AD-associated genes are associated with longitudinal cognitive decline by examining aggregate variation across these gene regions. In two single-sex cohorts of older, community-dwelling adults, we examined the association between SNPs in previously implicated gene regions and cognitive decline (age-adjusted person-specific cognitive slopes) using a Sequence Kernel Association Test (SKAT). In regions which showed aggregate significance, we examined the univariate association between individual AGE (2016) SNPs in the region and cognitive decline. Only two of the original AD-associated SNPs were significantly associated with cognitive decline in our cohorts. We identified significant aggregate-level associations between cognitive decline and the gene regions BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C in the allfemale cohort and significant associations with ABCA7, HLA cluster, MS4A6E, PICALM, PTK2B, SLC24A4, and SORL1 in the all-male cohort. We also identified a block of eight correlated SNPs in CD33 and several blocks of correlated SNPs in CELF1 that were significantly associated with cognitive decline in univariate analysis in the all-female cohort.
Introduction
Single nucleotide polymorphisms (SNPs) have been identified as risk/protective factors for Alzheimer's disease (AD). Variants in the well-studied APOE gene have the strongest known genetic association with AD. In addition to APOE, SNPs in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been identified in large meta-analyses as being associated with AD (Harold et al. 2009; Hollingworth et al. 2011; Lambert et al. 2013; Naj et al. 2011; Seshadri et al. 2010) . In general, the effect sizes for individual SNPs, other than those in APOE, are modest (odds ratios <1.25) and the extent to which these variants are causally linked to AD is still unclear.
While genome-wide association studies (GWAS) have been valuable platforms for identifying candidates for disease-related genetic variants, there are several limitations to these large-scale association studies. Most notably, the vast number of statistical comparisons being performed without a priori hypotheses requires corrections for multiple comparisons, thereby setting a stringent requirement to achieve statistical significance. In addition, large-scale GWAS have generally not examined additive or multiplicative SNP interactions within genomic regions. This is particularly problematic as collections of variants within genomic regions do not work in isolation and likely have a combined influence on phenotypic expression, particularly for complex phenotypes such as AD and cognitive decline (Schork et al. 2009; Torkamani et al. 2008) .
To address some of the limitations encountered with univariate SNP-based analysis, novel methods have been developed to examine groups of SNPs in aggregate. Aggregate SNP methods reduce the total number of tests performed and increase power by taking advantage of the linkage disequilibrium (LD) across multiple SNPs (Wu et al. 2010) . By reducing the number of tests and increasing power, smaller sample sizes are required compared with traditional GWAS. The Sequencing Kernel Association Test (SKAT) is one such method that can simultaneously test the association between multiple SNPs and a single outcome while controlling for covariates (Wu et al. 2011) . Significance from SKAT analysis for a particular gene provides additional evidence for the involvement of the gene in the phenotype and provides a more focused target to search for functional variation contributing to underlying biology.
We set out to determine whether established ADassociated genes are associated with longitudinal cognitive decline by examining aggregate variation across these gene regions in two populations of older adults. This analysis posits that variation across an entire gene region-rather than a single SNP in isolation-plays a role in cognitive decline.
Methods

Participants
We examined two longitudinal cohorts of Caucasian older adults, one male (Osteoporotic Fractures in Men-MrOS) and one female (Study of Osteoporotic Fractures-SOF). During the MrOS baseline examination from 2000 to 2002, 5994 community-dwelling men 65 years or older were enrolled at six clinical centers in the USA: Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California as previously described (Blank et al. 2005; Orwoll et al. 2005) . During the SOF baseline examination from 1986 to 1988, 9704 community-dwelling white women 65 years or older were enrolled from population-based listings in four areas of the USA: Baltimore, Maryland; Minneapolis, Minnesota; Pittsburgh, Pennsylvania; and Portland, Oregon as previously described (Cummings et al. 1990 ). For both studies, individuals were not eligible to participate if they reported bilateral hip replacement or required the assistance of another person in ambulation at the baseline examination. Written informed consent was obtained from all SOF and MrOS participants, and the Institutional Review Board at each study site approved the study. Only participants with at least two cognitive testing time points were retained (SOF N = 3267, MrOS N = 3026).
Measures
For each cohort, we examined cognitive decline over 10 years of follow-up using a global cognitive test (abbreviated Mini-Mental Status Examination (MMSE) in SOF, Modified Mini-Mental Examination (3MS) in MrOS); each test was administered up to four times. Cognitive decline (person-specific slope) was calculated using linear mixed-effects regression models adjusted for age (Gould et al. 2001) . Genotyping, imputation, and quality controls were performed identically in both cohorts using the Illumina HumanOmni1_Quad_v1-0 B array. Genotypes were called using the Illumina's BeadStudio calling algorithm. The sample quality control exclusion criteria were sample call rate <97 %, excessive autosomal heterozygozity, first and second degree relatives, genotypic sex mismatch using X and Y chromosome probe intensities, and gross chromosome abnormalities. Genotyped SNPs with GenTrain scores <0.6, cluster separation scores <0.4, call rates <97 %, or minor allele frequency (MAF) <0.01 were excluded. Also, autosomal SNPs with Hardy-Weinberg Equilibrium (HWE) p value <10-4 were excluded and genotype clusters for SNPs on chrX, chrY, chrXY, and chrMT (mitochondrial chromosomes) were reviewed manually. Autosomal SNPs (714,543) passed quality control. Imputation was done using MaCH (v 1.0.17, phasing) (Li and Abecasis 2006) and Minimac v 2011-08-12 beta (Howie et al. 2012) for HapMap phase II release 22 build 36, oriented on the positive strand. A combined panel of CEU, YRI, CHB, and JPT HapMap samples was used as a reference panel for the consensus-phased haplotypes.
Statistical analyses
First, we evaluated the relationship between the previously identified Bsentinel^SNPs associated with AD and cognitive decline (person-specific age-adjusted cognitive slopes as outcome) in our cohorts using linear regression adjusting for the first four cohort-specific principal components. The sentinel SNPs we considered achieved genome-wide significance in recent, large meta-analyses. Then, we evaluated the associations between cognitive decline and candidate genes across multiple SNPs simultaneously using the SKAT package in R with a MAF cutoff of ≥2 % for SNP inclusion in this analysis (Wu et al. 2011) . We considered multiple kernel functions: weighted and unweighted versions of the linear kernel and the identity-by-state (IBS) kernel. The linear kernel models each SNP as a variable in a regression model having its own beta coefficient. The IBS kernel models the aggregate variation using genetic similarity between individuals. The weighted kernel functions upweight rarer variants, whereas all SNPs are treated the same in the unweighted version (Wu et al. 2010) . We also considered a kernel function which allows for multiplicative SNP interactions within the gene region. The different kernel functions for a given gene region and sample are not independent tests but may provide clues to the structure or relationship of the SNPs underpinning the association. For each gene, we included all available SNPs 30 kb upstream and downstream from the gene boundaries (RefSeq NCBI36/ hg18), with two exceptions: NME8 for which we went 47 kb downstream and PICALM in which we went 88 kb upstream in order to capture the sentinel SNPs. The first four principal components (cohort specific) were included in SKAT analyses to control for population stratification. For genes which showed a significant association, we performed a further SKAT analysis dropping the sentinel SNPs and all other SNPs in high LD with the sentinel SNPs (R 2 ≥ 0.80 HapMap CEU from 1000 genomes). Gene-level p values for the primary SKAT analyses have not been adjusted for multiple comparisons as these analyses were based on a priori hypotheses. For gene regions exhibiting statistical significance (p value < 0.05) in the SKAT analysis after dropping the top associated SNPs, univariate analysis was performed on the remaining SNPs within the gene region in order to determine how additional SNPs at these loci contribute to cognitive decline (adjusted for first four cohort-specific principal components). P values for univariate analyses have been adjusted as noted in the results. Expression quantitative trait loci (eQTL) were examined for significant SNPs across ten human brain regions using the UK Brain Expression Consortium database (Ramasamy et al. 2014 ). Finally, we performed permutation tests to identify significant enrichment of nominally significant results. In each cohort, the SKAT analysis was repeated 350 times with a different permutation of cognitive slopes as the outcome.
Because the two cohorts used different cognitive tests and differed in composition in several ways, including sex and study initiation date, we did not combine the cohorts. Rather, we performed stratified analyses and compared the results from both cohorts qualitatively. Although SOF had a longer follow-up at the time of analysis, having been initiated earlier, for the purpose of consistency, we have restricted follow-up for both studies to the first 10 years after baseline.
Results
The average baseline age of male participants (MrOS) was 73.4 years (standard deviation (SD) 5.7); average baseline age of female participants (SOF) was 71.0 years (SD 4.9) (p < 0.001). MrOS participants were more likely to have high education (56 % with a college degree vs 18 % in SOF, p < 0.001). SOF participants had a higher number of cognitive assessments with 74 % of SOF participants having had four cognitive assessments as compared to 21 % of MrOS participants with four assessments (p < 0.001). The average baseline cognitive assessment score in both cohorts was high (24.8 ± 1.5 out of a possible score of 26 in SOF and 94.4 ± 4.5 out of a possible score of 100 in MrOS).
We first tested each sentinel SNP available in our data for an association with cognitive decline (Table 1) . Only two of the individual sentinel SNPs showed significant associations with cognitive decline in the female cohort (rs3764650 in ABCA7, p = 0.01; rs3865444 in CD33, p = 0.01). None of the top AD-associated SNPs were associated with cognitive decline in the male cohort. Ten of the 35 sentinel SNPs were not available in our data and could not be tested individually.
Next, we tested each gene region for aggregate association. Several gene regions showed significant aggregate associations with cognitive decline using one or more kernel functions: BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C in the female cohort and ABCA7, HLA cluster, PICALM, PTK2B, SLC24A4, and SORL1 in the male cohort ( Table 2 ). The significance was largely consistent regardless of whether the analytical method for assessing SNP structure/variation (kernel function) was linear or IBS. In contrast, most gene regions which showed any significance, showed significance using either weighted or unweighted methods, not both, which may provide some clue as to the rarity of the group of SNPs driving the significance. Two gene regions showed significance with the interaction kernel function CELF1 in women and SORL1 in men. We then tested each significant gene region for continued aggregate association with cognitive decline after removal of the sentinel SNP(s) which led us to these particular genomic regions of interest. After dropping the sentinel SNP(s) and all SNPs in LD with them (R 2 ≥ 0.80 HapMap CEU), the aggregate significance in gene regions which were significant in the primary analysis remained largely unchanged. Resulting p values along with the number of SNPs dropped is shown in Table 2 . Our data did not contain the sentinel SNP or any correlated SNPs for the HLA cluster, so the secondary analysis is identical to the primary analysis.
Next, we performed univariate analysis within significant gene regions to identify new candidate variants for cognitive decline. In all 11 gene regions which showed aggregate significance with cognitive decline, we found individual SNPs that were nominally significantly associated with cognitive decline in univariate analysis in their respective cohorts. After correction for multiple comparisons by gene region, only univariate associations in CD33 and CELF1 in the female cohort remained significant.
Univariate analysis in CD33 in the all-female cohort revealed a block of eight SNPs (rs273638, rs273639, rs1697553, rs2455069, rs12609179, rs1566576, rs1697573, rs273634) in strong LD which were individually significantly associated with greater cognitive decline (all unadjusted p = 0.0001, all p = 0.001 after adjustment for false discovery via Benjamini-Hochberg procedure (Benjamini and Hochberg 1995) (shown in Supplementary Fig. 1 ). These SNPs were not associated with CD33 gene expression across ten brain regions (Sherry et al. 2001) . Several of the CD33 SNPS exhibit highly significant effects on hyaluronan synthase-1 (HAS1) expression in the temporal cortex, with the strongest effect for rs2455069 (p = 1.4e-05), which encodes an Arg69Gly substitution in CD33.
Also in the female cohort, we identified eight SNPs in CELF1 which remained significant (p = 0.002-0.02) after adjustment for false discovery within the gene. Two blocks of SNPs (rs11604680, rs1317149, rs4752845 and rs7124681, rs7928842) were associated with better cognitive performance; another block of three SNPs (rs2242081, rs10742814, rs11039280) were associated with worse cognitive performance. The rs11604680 and rs1317149 SNPs from the first block are located 3′ of CELF1. Each of these SNPs was associated with CELF1 expression in the hippocampus (rs1317149, p = 0.025, and rs4752845, p = 0.015). The remaining SNPs are intronic within CELF1 and are associated with gene expression CELF1 in the thalamus. The rs7124681 and rs7928842 SNPs from the second SNP block that were associated with improved cognitive performance exhibited lower CELF1 expression with each copy of the minor allele (rs7124681, p = 0.022, and rs7928842, p = 0.013). The three SNPs from block three that were associated with poor cognitive function exhibited higher CELF1 expression with each copy of the minor allele (rs2242081 and rs10742814, p = 0.02, and rs11039280, p = 0.027). Several of the CELF1 SNPS exhibit highly significant effects on MTCH2 expression in the cerebral cortex, with the strongest effect for rs7928842 (p = 8.1e-07).
Finally, we performed permutation tests to identify significant enrichment of nominally significant associations across multiple gene regions. We focused the permutation analyses on the linear and weighted linear kernel functions since the linear and IBS kernel functions performed similarly in the original analyses. We considered a gene region Bsignificant^if the p value for either of the kernel functions was <0.05. In our main analysis, we found significant results for six gene regions in each cohort. The probability of finding significant results for six or more gene regions in the female cohort was 0.006, and the probability of six or more significant gene regions in the male cohort was 0.01.
Discussion
We examined gene regions based on previously identified AD-associated SNPs using an aggregate testing method (SKAT) and found that several regions were associated with cognitive decline in each cohort. Among SOF women, BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C1 were significantly associated with cognitive decline and remained so even after removing the sentinel SNPs and all other SNPs in high LD (R 2 ≥ 0.8, HapMap CEU) with the sentinels. Among MrOS men, ABCA7, HLA cluster, PICALM, PTK2B, SLC24A4, and SORL1 were significantly associated with cognitive decline and remained significant after dropping the sentinel SNP and SNPs in LD with the sentinel SNP.
It is perhaps not surprising that dropping the top ADassociated SNPs did not alter the gene-level aggregate since the individual AD-associated SNPs were largely not associated with cognitive decline in these cohorts. In fact, CD33 in SOF was the only gene region that had both a significant AD-associated SNP and showed a significant aggregate association with cognitive decline.
The fact that some gene regions exhibited aggregate associations using only kernel functions which upweight rarer SNPs (BIN1, CR1, and HLA cluster in females; HLA cluster and PTK2B in males) and others only showed association using unweighted kernel functions (CD33 and CELF1 in females; SORL1 in males) likely reflects the SNP characteristics underlying the gene-level associations. The SNPs which were nominally significant in univariate analysis in BIN1 and CR1 in the female cohort had relatively rare minor alleles (MAF 0.02-0.07). In contrast, in CD33 and CELF1, which were only significant in the female cohort using unweighted kernel functions, the nominally significant SNPs had a much higher MAF (0.06-0.44, with most SNPs in the 0.31-0.44 range). A similar result occurred in the all-male cohort: in nominally significant SNPs in PTK2B, which showed weighted aggregate significance, the minor alleles were less common (MAF 0.02-0.16); the MAF was higher in nominally significant SNPs from SORL1, which showed unweighted aggregate significance (0.04-0.50, with MAF for most SNPs >0.20). The HLA cluster was a curious departure from this pattern in both cohorts. Despite having aggregate significance in both cohorts using only kernel functions which upweight rarer SNPs, only 11 % of the nominally significant SNPs in the female cohort and 40 % of the nominally significant SNPs in the male cohort had MAF ≤ 0.05. The reason for this result is unclear, although none of the SNPs were strongly associated enough to remain significant after adjustment.
In addition to a significant aggregate association with CD33, we found eight SNPs forming an LD block in CD33 that were also significantly associated with greater cognitive decline in univariate analysis. CD33 is a transmembrane glycoprotein, a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs). CD33 is known to perform a number of functions including cell-cell communication inhibiting immune response (Crocker et al. 2012; Pillai et al. 2012) , immune cell growth, adhesion processes in immune or malignant cells, and endocytosis (Crocker et al. 2007; von Gunten and Bochner 2008) . Recent research has focused on understanding how CD33 may modify AD susceptibility or disease course. CD33 expression is modestly increased in AD, and the previously identified protective minor allele of the top AD-associated SNP (rs3865444) has been associated with reductions in CD33 microglia expression (Griciuc et al. 2013; Malik et al. 2013) . Microglia are hypothesized to play a role in phagocytosis of amyloid-beta, a primary pathological protein in AD, and recent research has borne out an association between the protective allele and increased uptake of amyloid-beta, as well as reduced amyloid plaque burden and insoluble amyloid-beta levels (Bradshaw et al. 2013; Griciuc et al. 2013) . In our study, the large eight-SNP LD block in CD33 exhibiting significant univariate associations with cognitive decline is located within the 5′ end of the gene region including the promoter, suggesting it may affect expression levels or protein function. However, these SNPs did not impact CD33 expression across several brain regions in a large eQTL database. It is possible that these SNPs impact expression of nearby genes and not CD33. Indeed, several of these SNPs, including rs2455069 encoding the Arg69Gly substitution in CD33, were associated with strong effects on HAS1 gene expression in the temporal cortex, a region of the brain affected in AD. While the HAS1 gene is approximately 500 kb away from rs2455069, Ramasamy et al. (2014) observed that numerous brain eQTL signals were within 1 Mb of their target gene and often acted heterogeneously among genomic regions and exons. Hyaluronan (encoded by HAS1) transcription increases with aging. HAS1 is transcriptionally upregulated in astrocytes during normative aging and is linked to the accumulation of the hyaluronan in gray matter where it potentially inhibits astrogliosis and limits oligodendrocyte progenitor cell maturation (Cargill et al. 2012) . Further study is required to identify the function of rs2455069 and whether its effects on neurodegeneration are mediated through CD33 or another gene (e.g., HAS1).
In addition to the strong aggregate result in CELF1 in the female cohort, we also found eight SNPs which were significantly associated with greater cognitive decline in the CELF1 region. The CELF family of proteins are involved in the regulation of RNA processing including pre-mRNA alternative splicing, RNA editing, deadenylation, mRNA stability, and translation. CELF proteins have been implicated in a number of disease including AD, potentially through the regulation of tau protein aggregates (Dasgupta and Ladd 2012) . Interestingly, the two CELF1 SNPs that were associated with improved cognitive performance exhibited lower CELF1 expression levels in the thalamus and the three CELF1 SNPs that were associated with poor cognitive function exhibited higher CELF1 expression in the thalamus. While these results suggest that the CELF1 SNPs impacting cognition may be modifying expression levels in the thalamus, it is possible that these SNPs are also impacting expression of nearby genes. Several of these SNPs are highly associated with MTCH2 expression levels in the cerebral cortex. MTCH2 is located approximately 100 kb away from rs7928842, the SNP with the strongest effect on MTCH2 expression. MTCH2 encodes mitochondrial carrier 2 which likely plays a role in cellular apoptosis (PMID nos. 18614015 and 15899861) and has been associated with obesity (PMID no. 21795451).
Although the sentinel SNP from CR1 was not significantly associated with cognitive decline in either sample, CR1 showed the strongest aggregate association with the weighted kernel functions in SOF. We found nine nominally significant SNPs, but none were significant after adjusting for multiple comparisons. CR1 is one of 30 proteins that make up the complement system, which participate in the regulation of inflammation and immune reaction. CR1 is expressed in the brain and may play a role in amyloid-beta clearance (Crehan et al. 2012) .
To our knowledge, this analysis is the first to look at aggregate-level genetic associations with cognitive decline. Using previously identified AD-associated SNPs as sentinels, we targeted the entire gene region to assess whether there was aggregate association with cognitive decline, with and without the sentinel SNP. This approach allowed us to test whether variation across the entire gene region impacts cognitive decline. Both SOF and MrOS are community-based samples rather than clinical samples, giving our results greater generalizability. Another strength of our analysis was the ability to follow participants longitudinally to capture cognitive decline rather than simply observing cognitive status at a single time point, which can be subject to greater confounding. Although several of the sentinel SNPs and gene regions were associated with cognitive decline in each cohort, it is unclear why the results in the two cohorts differed. The most obvious difference between the cohorts is in their single-sex composition. There may be biological differences in risk of cognitive decline due to sex-related differences in hormones, immune regulation, inflammatory response, and comorbidities. There were also differences in cognitive testing: SOF used a less sensitive global cognitive test (MMSE); however, the participants were more likely to have had four testing time points. Thus, cognitive change observed in SOF may have been quite pronounced. By contrast, the MrOS study used a more sensitive global cognitive test (3MS), but many of the participants only had two testing time points, which may not have been adequate to observe substantial change or may have created noise by identifying inconsequential change. This analysis had several limitations. First, we were unable to test several of the sentinel SNPs because they were unavailable in our data. Second, the candidate genes we selected were motivated by AD-associated SNPs, whereas we have examined cognitive decline, which likely results from multiple pathologies, not just AD. AD is the most common form of dementia, and a large proportion of the cognitive decline that we observed in these cohorts is probabilistically due to AD (Barker et al. 2002) . But the fact that the top AD-associated SNPs were largely unassociated with cognitive decline in both cohorts might suggest that AD-targeted regions do not translate well to general cognitive decline. Finally, the MMSE is not the most sensitive test for capturing early cognitive decline but more sensitive cognitive tests were unavailable in the early years of the SOF study.
Many of the sentinel SNPs and associated gene regions were not associated with cognitive decline in either sample. This finding is supported by two recent studies in other cohorts which found limited or no association between risk genes for AD and cognitive aging (Harris et al. 2014; Verhaaren et al. 2013) . One potential explanation for the lack of consistent associations is that the gene regions suggested by the top AD SNPs were not causally associated with AD, and the associated SNPs are in LD with the causal SNPs in a different genomic region. Another possibility is that the AD-associated sentinel SNPs which informed our analysis are AD specific and other pathologies such as vascular disease have stronger contributions to the cognitive decline in these cohorts. A recent study found evidence of synergistic interaction effects among ADassociated genes and the development of AD (Ebbert et al. 2014) . Thus, an association between AD risk genes and cognitive decline may involve more complicated relationships than have been tested here. Another possible explanation is that our study was insufficiently powered.
In conclusion, we identified aggregate-level associations between cognitive decline and the gene regions ABCA7, BIN1, CD33, CELF1, CR1, HLA, MEF2C, PICALM, PTK2B, SLC24A4, and SORL1. In addition to the gene-level association, novel CD33 and CELF1 SNP associations independent of previously identified sentinel SNPs were identified for cognitive decline. If replicated in independent population-based studies of cognitive function, our results suggest that CD33 and CELF1 may be important targets for functional followup studies related to cognitive aging.
